Introduction to the nutrigenomics of essential fatty acids

For decades, global nutritional recommendations have treated populations homogeneously, suggesting standard intakes of macro- and micronutrients under the premise that human metabolism operates with mathematical uniformity. However, modern genomic science has dismantled this simplification. Nutrigenomics, the study of how genetic variation influences dietary response and how nutrients modulate gene expression, has revealed that the effectiveness of certain nutrients depends intrinsically on an individual's genetic code. Essential fatty acids (EFAs), particularly the omega-3 family, represent one of the most fascinating paradigms of this gene-diet interaction. Although traditionally hailed for their cardioprotective and anti-inflammatory effects, the assimilation and biological conversion of these lipids varies dramatically among individuals, making widespread prescriptions ineffective at best and physiologically useless at worst for certain genotypes.

The myth of the "universal omega-3": Why we don't all respond the same way

The scientific and medical community has promoted the consumption of omega-3 fatty acids as a cornerstone of cardiovascular, brain, and metabolic health. However, large-scale clinical trials often yield contradictory results, with population subgroups experiencing no improvement in their inflammatory or lipid markers after supplementation. This phenomenon, previously attributed to experimental design flaws or poor adherence, is now understood through the lens of nutrigenomics. Our DNA contains specific variations (polymorphisms) that determine the efficiency with which our liver and peripheral tissues process the fats we ingest. What results in a potent cascade of inflammation-resolving molecules for one individual may be biologically inert for another due to enzymatic bottlenecks dictated by their genetics. This interindividual variability means that the "universal omega-3" is a clinical myth; true efficacy requires a deep understanding of each patient's unique genetic and enzymatic profile.

Differentiating the sources: ALA, EPA and DHA at the biochemical level

To understand the genetic bottleneck, it is imperative to distinguish between the different molecular forms of omega-3. Alpha-linolenic acid (ALA) is a short-chain (18 carbons) polyunsaturated fatty acid found predominantly in plant sources such as flax seeds, chia seeds, and walnuts. However, ALA is biologically inactive in most critical cell signaling pathways. For the human body to reap the benefits of omega-3, ALA must be elongated and biochemically desaturated in the liver into eicosapentaenoic acid (EPA, 20 carbons) and subsequently into docosahexaenoic acid (DHA, 22 carbons). EPA and DHA (present directly in marine sources such as oily fish and microalgae) are the true bioactive agents, responsible for cell membrane fluidity, neuronal development, and the synthesis of anti-inflammatory lipid mediators. The crux of the nutrigenomic problem lies in the fact that the conversion of ALA to EPA and DHA is a highly inefficient enzymatic process in humans, usually ranging between 5% and 10%, but which can fall drastically to less than 1% depending on specific genetic variants that regulate the enzymes responsible for this process.

The genetics behind lipid metabolism (FADS1 and FADS2)

The molecular epicenter of omega-3 and omega-6 fatty acid assimilation lies in a cluster of genes on chromosome 11 (11q12-13.1), specifically the FADS1 and FADS2 genes (Fatty Acid Desaturase 1 and 2). These genes encode the delta-5 and delta-6 desaturase enzymes, respectively. These enzymes are the critical biochemical workers that add double bonds to the carbon chains of dietary fatty acids, a non-negotiable step for the endogenous synthesis of the long-chain polyunsaturated fatty acids (LC-PUFAs) EPA and DHA from their plant precursor, ALA. The activity of these desaturases is not constant; it is modulated by genetics and the environment and is the primary limiting factor in the tissue bioavailability of bioactive lipids.

The enzymatic role of desaturases in elongation

The metabolic pathway of essential fatty acids is an intricate dance of competing enzymes. The enzyme delta-6 desaturase (encoded by FADS2) performs the first and most critical rate-limiting step: desaturating ALA. Subsequently, an elongase enzyme adds carbons, and finally, delta-5 desaturase (encoded by FADS1) steps in to produce EPA. It is crucial to understand that these same enzymes (FADS1 and FADS2) are also responsible for metabolizing the parallel family of omega-6 fatty acids (from plant linoleic acid to pro-inflammatory arachidonic acid). Since both types of fats (omega-3 and omega-6) compete for the same limited pool of desaturase enzymes, a dietary excess of omega-6 (typical of Western diets rich in processed seed oils) can "sequester" these enzymes, effectively halting the endogenous synthesis of EPA and DHA, regardless of genetics. However, genetics determines the baseline capacity of this enzymatic machinery.

Key single nucleotide polymorphisms (SNPs) and their metabolic impact

Research in genome-wide association studies (GWAS) has consistently identified single nucleotide polymorphisms (SNPs) in the FADS gene cluster that drastically alter enzyme activity. One of the most studied SNPs is rs174537 near the FADS1 gene. Individuals carrying the minor allele (T allele) exhibit significantly reduced delta-5 desaturase activity. Biologically, this translates into a systemic accumulation of intermediate lipid precursors and a marked deficiency in the endogenous production of EPA and arachidonic acid. Another critical SNP is rs174575 in FADS2. Individuals with unfavorable genotypes at these gene loci (colloquially known as "slow metabolizers") are metabolically unable to maintain optimal levels of EPA and DHA in cell plasma and membrane phospholipids if they rely exclusively on plant precursors (ALA). For these individuals, plant-based diets that do not include direct algae supplementation (rich in preformed DHA/EPA) may result in silent states of omega-3 cellular deficiency, exacerbating long-term phenotypic vulnerabilities.

Clinical consequences: Inflammation and cardiovascular health

The impact of having a genetic profile that is inefficient in fatty acid conversion transcends mere cellular biochemistry; it has profound and measurable clinical consequences, particularly in the domains of systemic immunology and cardiovascular pathology. Long-chain omega-3 fatty acids (EPA and DHA) are not simply structural building blocks of cell membranes (such as neural tissue or the retina), but are the direct substrates for a vast network of local hormones and immunomodulators.

Genetic modulation of cytokines and eicosanoids

When cell membranes are rich in arachidonic acid (an omega-6 fatty acid), in response to an inflammatory stimulus, the enzymes cyclooxygenase (COX) and lipoxygenase (LOX) produce a storm of highly pro-inflammatory eicosanoids, such as prostaglandin series 2 (PGE2) and leukotrienes series 4 (LTB4). Conversely, if membranes are enriched with EPA and DHA, these same enzymes produce much less inflammatory signaling molecules (prostaglandin series 3, leukotrienes series 5) and, more critically, specialized inflammation-resolving metabolites (SPMs) called resolvins, protectins, and maresins. Individuals with "slow" FADS genetic variants, having lower levels of tissue EPA and DHA, are biologically predisposed to a chronic, low-grade inflammatory state. Their immune cells overproduce chronic pro-inflammatory cytokines, creating a systemic microenvironment that facilitates ongoing tissue damage and oxidative stress.

Cardiovascular risk and the paradox of ineffective supplementation

This propensity for chronic systemic inflammation, mediated by gene-diet interactions, is the primary driver underlying atherosclerosis and endothelial dysfunction. Plaque buildup in the arteries is not merely a problem of high cholesterol, but rather a maladaptive immune response to oxidized lipids in the arterial walls. Individuals with inefficient FADS genotypes statistically exhibit higher fasting triglyceride levels and increased arterial stiffness, drastically raising their cardiovascular (CVD) risk. This explains the "clinical paradox" observed in numerous studies: when the general population is advised to increase their consumption of walnuts or flaxseed (ALA) for heart health, individuals with unfavorable FADS1/FADS2 polymorphisms do not derive any cardioprotective benefit, as their bodies fail to synthesize the necessary resolvent molecules to soothe the vascular endothelium. Their genetic code demands a higher level of nutritional intervention.

From science to your plate: Practical application and personalized nutrition

The era of one-size-fits-all diets is over. With the dramatic drop in the cost of genetic sequencing and the exponential advancement of health data analysis, consumers now have the power to look "under the hood" of their own biology. Translating knowledge of FADS genotypes into viable health strategies is at the forefront of functional and preventive medicine.

How to interpret your genetic profile to adjust your diet

If a nutrigenomic test reveals that you carry risk variants in FADS1 (e.g., rs174537 T allele) or FADS2, the dietary approach must radically shift from precursor supplementation to the direct intake of bioactive end products. For a "slow metabolizer," massive consumption of flaxseed or chia oil will be metabolically ineffective for inflammation. These individuals must obtain preformed EPA and DHA directly from superior dietary sources: wild-caught fatty fish (salmon, mackerel, sardines) consumed several times a week, or clinical supplementation with ultra-purified fish oil (or microalgae oil, the only direct and viable vegan source of DHA/EPA). Furthermore, it is clinically vital for these individuals to aggressively reduce their intake of omega-6 fatty acids from industrial vegetable oils (sunflower, corn, soy) to avoid residual competitive inhibition of their already impaired desaturase enzymes.

Precision nutrition and the future with genomic tools

Knowing our genetic profile is not a death sentence, but rather an operational instruction manual. The promise of nutrigenomics lies in empowering individuals to take control of their health through precise and actionable data. In this context, specialized digital tools are bridging the gap between the genetic laboratory and the kitchen table. For example, advanced precision nutrition platforms such as Oorenji They integrate your metabolic and phenotypic data to generate highly personalized dietary recommendations and dynamic eating plans. Instead of navigating blindly through a sea of supplements and fad diets, the nutrition of the future, powered by artificial intelligence and clinically validated, allows for the optimization of specific enzymatic pathways, such as those for fatty acids, ensuring vibrant cellular health and optimized longevity at the molecular level.

Scientific references

• Chilton, F.H., et al. (2014). «Precision nutrition and omega-3 polyunsaturated fatty acids: A case for personalized supplementation approaches for the prevention and management of human diseases.» Nutrients, 6(4), 1332-1349. (Genomic review and dietary modulation).
• Merino, DM, et al. (2010). "Polymorphisms in FADS1 and FADS2 alter desaturase activity in young Caucasian and Asian adults." Molecular Genetics and Metabolism, 101(1), 74-80. (In vivo study on SNPs and fatty acid elongation).
• Koletzko, B., et al. (2019). "The role of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations." Journal of Perinatal Medicine(Clinical evidence of molecular requirements for DHA).
• Serhan, C.N. (2014). "Pro-resolving lipid mediators are leads for resolution physiology." Nature, 510(7503), 92-101. (Biochemical mechanisms of omega-3-derived resolvins and protectins).
• Lemaitre, R.N., et al. (2011). "Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium." PLoS Genetics, 7(7). (Large-scale GWAS on FADS and systemic lipid levels).